Review



aro hsd  (Arrowhead Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Arrowhead Pharmaceuticals aro hsd
    Aro Hsd, supplied by Arrowhead Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/aro+hsd/pmc12965242-26-22-23
    Average 86 stars, based on 1 article reviews
    aro hsd - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
    Article Snippet: HSD17B13 , ARO-HSD , Arrowhead Pharma- ceuticals Inc. , siRNA , NCT04202354 , , , , Phase 1/2 , Healthy volunteers and individuals with NASH or suspected NASH , Completed.

    Article Title: Framework to identify innovative sources of value creation from platform technologies.
    Article Snippet: Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals enters exclusive license agreement with GSK for ARO- HSD (2021). https://ir.arrowheadpharma.com/news- releases/news- release- details/ arrowhead- pharmaceuticals- enters- exclusive- license- agreement- gsk.

    Article Title: Therapeutic RNA Delivery for COVID and Other Diseases
    Article Snippet: Arrowhead Pharmaceuticals , ARO‐HSD: Liver diseases , Reduce production of hydroxysteroid dehydrogenase HSD17B13 , Subcutaneous , Phase I: NCT04202354 , Phase I recruiting in progress..

    Article Title: News
    Article Snippet: US-based Arrowhead Pharmaceuticals has entered into an exclusive licence agreement with GSK, under which GSK will develop and commercialise ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with non-alcoholic steatohepatitis (NASH).

    Article Title: Oligonucleotide therapies for nonalcoholic steatohepatitis
    Article Snippet: ARO-HSD (Arrowhead Pharmaceuticals) , HSD17B13 , siRNA/siRNA-GalNAc conjugate , NASH , phase 1 , NCT04202354 , Mak et al. .

    Article Title: Drug development advances in human genetics‐based targets
    Article Snippet: ARO‐HSD , Arrowhead Pharmaceuticals Inc , Phase 2 clinical , Liver disease; NASH; ALD , , .

    Article Title: Oligonucleotide Therapeutics: From Discovery and Development to Patentability
    Article Snippet: ARO-HSD , HSD17B13 , Expression inhibition , Gastrointestinal , Phase II , Arrowhead Pharmaceuticals.

    Inhibition:

    Article Title: Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
    Article Snippet: HSD17B13 , ARO-HSD , Arrowhead Pharma- ceuticals Inc. , siRNA , NCT04202354 , , , , Phase 1/2 , Healthy volunteers and individuals with NASH or suspected NASH , Completed.

    Article Title: Framework to identify innovative sources of value creation from platform technologies.
    Article Snippet: Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals enters exclusive license agreement with GSK for ARO- HSD (2021). https://ir.arrowheadpharma.com/news- releases/news- release- details/ arrowhead- pharmaceuticals- enters- exclusive- license- agreement- gsk.

    Article Title: Therapeutic RNA Delivery for COVID and Other Diseases
    Article Snippet: Arrowhead Pharmaceuticals , ARO‐HSD: Liver diseases , Reduce production of hydroxysteroid dehydrogenase HSD17B13 , Subcutaneous , Phase I: NCT04202354 , Phase I recruiting in progress..

    Article Title: News
    Article Snippet: US-based Arrowhead Pharmaceuticals has entered into an exclusive licence agreement with GSK, under which GSK will develop and commercialise ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with non-alcoholic steatohepatitis (NASH).

    Article Title: Oligonucleotide therapies for nonalcoholic steatohepatitis
    Article Snippet: ARO-HSD (Arrowhead Pharmaceuticals) , HSD17B13 , siRNA/siRNA-GalNAc conjugate , NASH , phase 1 , NCT04202354 , Mak et al. .

    Article Title: Drug development advances in human genetics‐based targets
    Article Snippet: ARO‐HSD , Arrowhead Pharmaceuticals Inc , Phase 2 clinical , Liver disease; NASH; ALD , , .

    Article Title: Oligonucleotide Therapeutics: From Discovery and Development to Patentability
    Article Snippet: ARO-HSD , HSD17B13 , Expression inhibition , Gastrointestinal , Phase II , Arrowhead Pharmaceuticals.



    Similar Products

    aro hsd  (Arrowhead Pharmaceuticals)
    86
    Arrowhead Pharmaceuticals aro hsd
    Aro Hsd, supplied by Arrowhead Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/aro+hsd/pmc12965242-26-22-23
    Average 86 stars, based on 1 article reviews
    aro hsd - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    aro-hsd  (Arrowhead Pharmaceuticals)
    90
    Arrowhead Pharmaceuticals aro-hsd
    Aro Hsd, supplied by Arrowhead Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/aro+hsd/pm40388610-517-11-14
    Average 90 stars, based on 1 article reviews
    aro-hsd - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    aro-hsd injection  (Arrowhead Pharmaceuticals)
    90
    Arrowhead Pharmaceuticals aro-hsd injection
    Other examples of tri-GalNAc conjugate therapeutic agents in clinical trials [ <xref ref-type= 183 ]." width="250" height="auto" />
    Aro Hsd Injection, supplied by Arrowhead Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/aro+hsd/pmc12026779-33-26-35
    Average 90 stars, based on 1 article reviews
    aro-hsd injection - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    gsk4532990 aro-hsd  (Glaxo Smith)
    90
    Glaxo Smith gsk4532990 aro-hsd
    GalNAc–siRNA in the clinics or clinical development. Note: the lists of clinical trials and published results are not exhaustive
    Gsk4532990 Aro Hsd, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/gsk4532990/pmc11609720-421-0-2
    Average 90 stars, based on 1 article reviews
    gsk4532990 aro-hsd - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    aro-hsd (gsk4532990) sirna  (Arrowhead Pharmaceuticals)
    90
    Arrowhead Pharmaceuticals aro-hsd (gsk4532990) sirna
    GalNAc–siRNA in the clinics or clinical development. Note: the lists of clinical trials and published results are not exhaustive
    Aro Hsd (Gsk4532990) Sirna, supplied by Arrowhead Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aro-hsd/aro+hsd++gsk4532990++sirna/pmc11044058-486-1-6
    Average 90 stars, based on 1 article reviews
    aro-hsd (gsk4532990) sirna - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Other examples of tri-GalNAc conjugate therapeutic agents in clinical trials [ <xref ref-type= 183 ]." width="100%" height="100%">

    Journal: International Journal of Molecular Sciences

    Article Title: Recent Update on siRNA Therapeutics

    doi: 10.3390/ijms26083456

    Figure Lengend Snippet: Other examples of tri-GalNAc conjugate therapeutic agents in clinical trials [ 183 ].

    Article Snippet: ARO-HSD , NCT04202354 , Study of ARO-HSD in Healthy Volunteers and Patients with Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH , Completed , Non-alcoholic Steatohepatitis , DRUG: ARO-HSD Injection DRUG: sterile normal saline (0.9% NaCl) , Arrowhead Pharmaceuticals , PHASE1 , Interventional , 23 November 2021.

    Techniques: Clinical Proteomics, Injection, Sterility, Saline, Virus, Infection

    GalNAc–siRNA in the clinics or clinical development. Note: the lists of clinical trials and published results are not exhaustive

    Journal: RSC Medicinal Chemistry

    Article Title: Hepatocyte targeting via the asialoglycoprotein receptor

    doi: 10.1039/d4md00652f

    Figure Lengend Snippet: GalNAc–siRNA in the clinics or clinical development. Note: the lists of clinical trials and published results are not exhaustive

    Article Snippet: GSK4532990 (ARO-HSD, GlaxoSmithKline, phase II), ALN-HSD (Alnylam, in collaboration with Regeneron, phase II), ARO-PNPLA3 (JNJ-75220795, Arrowhead), LY3849891 (Eli Lilly, phase I), LY3885125 (Eli Lilly, phase I), ALN-PNP (Alnylam, phase I), NN6581 (Novo Nordisk, phase I), NN6582 (Novo Nordisk, phase I), and OLX702A (OLX75016, OliX, phase I) are being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH).

    Techniques: Clinical Proteomics, Infection, Coagulation